PTPN11

PTPN11
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 2SHP, 3B7O, 3MOW, 3O5X, 3TKZ, 3TL0, 4DGP, 4DGX, 4GWF, 4H1O, 4JE4, 4JEG, 3ZM0, 3ZM1, 3ZM2, 3ZM3, 4H34, 4JMG, 4NWF, 4NWG, 4OHD, 4OHE, 4OHH, 4OHI, 4OHL, 4PVG, 4RDD, 4QSY, 5DF6, 5IBS, 5EHP, 5EHR, 5I6V, 5IBM
Identifiers
Aliases	PTPN11 , BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2, protein tyrosine phosphatase, non-receptor type 11, protein tyrosine phosphatase non-receptor type 11
External IDs	OMIM: 176876; MGI: 99511; HomoloGene: 2122; GeneCards: PTPN11; OMA:PTPN11 - orthologs
Gene location (Human) Chr. Chromosome 12 (human) [1] Band 12q24.13 Start 112,418,351 bp [1] End 112,509,918 bp [1]
Gene location (Mouse) Chr. Chromosome 5 (mouse) [2] Band 5|5 F Start 121,268,596 bp [2] End 121,329,460 bp [2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in internal globus pallidus dorsal motor nucleus of vagus nerve Brodmann area 23 visceral pleura parietal pleura subthalamic nucleus pars reticulata inferior olivary nucleus Epithelium of choroid plexus external globus pallidus Top expressed in renal corpuscle Epithelium of choroid plexus utricle medullary collecting duct retinal pigment epithelium substantia nigra ciliary body iris endocardial cushion primitive streak More reference expression data BioGPS More reference expression data
Gene ontology Molecular function phospholipase binding phosphoprotein phosphatase activity insulin receptor binding phosphatase activity receptor tyrosine kinase binding peptide hormone receptor binding protein binding non-membrane spanning protein tyrosine phosphatase activity hydrolase activity phosphatidylinositol-4,5-bisphosphate 3-kinase activity 1-phosphatidylinositol-3-kinase activity cell adhesion molecule binding protein tyrosine phosphatase activity phosphotyrosine residue binding protein domain specific binding D1 dopamine receptor binding insulin receptor substrate binding protein tyrosine kinase binding protein kinase binding Cellular component cytoplasm cytosol mitochondrion nucleus nucleoplasm protein-containing complex Biological process dephosphorylation megakaryocyte development positive regulation of signal transduction negative regulation of insulin secretion regulation of cell adhesion mediated by integrin atrioventricular canal development intestinal epithelial cell migration organ growth epidermal growth factor receptor signaling pathway negative regulation of growth hormone secretion axonogenesis glucose homeostasis regulation of protein export from nucleus multicellular organism growth regulation of multicellular organism growth lipid metabolism ephrin receptor signaling pathway abortive mitotic cell cycle DNA damage checkpoint signaling protein dephosphorylation T cell costimulation platelet formation microvillus organization positive regulation of mitotic cell cycle genitalia development platelet activation fibroblast growth factor receptor signaling pathway heart development brain development regulation of type I interferon-mediated signaling pathway hormone-mediated signaling pathway integrin-mediated signaling pathway Bergmann glial cell differentiation homeostasis of number of cells within a tissue inner ear development platelet-derived growth factor receptor signaling pathway negative regulation of cortisol secretion peptidyl-tyrosine dephosphorylation ERBB signaling pathway negative regulation of hormone secretion triglyceride metabolic process hormone metabolic process positive regulation of hormone secretion negative regulation of cell adhesion mediated by integrin regulation of protein-containing complex assembly face morphogenesis cerebellar cortex formation leukocyte migration multicellular organismal reproductive process phosphatidylinositol phosphate biosynthetic process neurotrophin TRK receptor signaling pathway phosphatidylinositol-3-phosphate biosynthetic process axon guidance positive regulation of ERK1 and ERK2 cascade cellular response to epidermal growth factor stimulus positive regulation of protein kinase B signaling cytokine-mediated signaling pathway interleukin-6-mediated signaling pathway cellular response to cytokine stimulus cellular response to mechanical stimulus positive regulation of interferon-beta production positive regulation of interleukin-6 production positive regulation of tumor necrosis factor production positive regulation of glucose import positive regulation of insulin receptor signaling pathway Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 5781 19247 Ensembl ENSG00000179295 ENSMUSG00000043733 UniProt Q06124 P35235 RefSeq (mRNA) NM_002834 NM_080601 NM_001330437 NM_001374625 NM_018508 NM_001109992 NM_011202 RefSeq (protein) NP_001317366 NP_002825 NP_542168 NP_001361554 NP_001103462 NP_035332 Location (UCSC) Chr 12: 112.42 – 112.51 Mb Chr 5: 121.27 – 121.33 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) also known as protein-tyrosine phosphatase 1D (PTP-1D), Src homology region 2 domain-containing phosphatase-2 (SHP-2), or protein-tyrosine phosphatase 2C (PTP-2C) is an enzyme that in humans is encoded by the PTPN11 gene. PTPN11 is a protein tyrosine phosphatase (PTP) Shp2. ^{[5] [6]}

PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains two tandem Src homology-2 domains, which function as phospho-tyrosine binding domains and mediate the interaction of this PTP with its substrates. This PTP is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are a cause of Noonan syndrome as well as acute myeloid leukemia. ^[7]

Evolution: Although lost in rodents and higher primates, most jawed vertebrates, including sharks, have a second ancient molecule that is very similar to PTPN11 (SHP-2) and has been named SHP-2like (SHP-2L). ^[8] In zebrafish, SHP-2 and SHP-2L have overlapping functional abilities. ^[9] SHP-2 and SHP-2L are quite distinct from SHP-1 (PTPN6). ^[8]

Structure

PTPN11 encodes the protein tyrosine phosphatase SHP2, which has a modular structure essential for its regulatory function in cell signaling. SHP2 consists of two tandem Src homology 2 (SH2) domains at the N-terminus (N-SH2 and C-SH2), followed by a catalytic protein tyrosine phosphatase (PTP) domain and a C-terminal tail containing tyrosyl phosphorylation sites. ^{[10] [11]} In its inactive, auto-inhibited conformation, the N-SH2 domain binds intramolecularly to the PTP catalytic domain, blocking substrate access to the active site. ^{[12] [11]} Upon binding to phosphotyrosyl residues on target proteins, the N-SH2 domain undergoes a conformational change that releases the PTP domain, thereby activating the enzyme. ^{[12] [10] [11]} The catalytic domain itself adopts a conserved fold characteristic of classical PTPs, featuring a catalytic loop (WPD loop) that undergoes conformational changes during substrate binding and catalysis. ^[12] This structural arrangement allows SHP2 to tightly regulate signaling pathways by selectively dephosphorylating substrates involved in cell growth, differentiation, and migration. ^[10] Mutations disrupting the interface between the N-SH2 and PTP domains can lead to constitutive activation or impairment of SHP2, underlying diseases such as Noonan syndrome and certain leukemias. ^{[13] [10]} The overall structure has been elucidated by multiple crystallographic studies, revealing both the auto-inhibited and active states, which provide insight into its mechanism of regulation and function in diverse cellular contexts. ^{[12] [11] [10]}

Function

PTPN11 encodes SHP2, a ubiquitously expressed protein tyrosine phosphatase that plays a important role in regulating cell signaling pathways, most notably the RAS/MAPK cascade, which controls cell proliferation, differentiation, migration, and survival. SHP2 acts as a positive regulator of signal transduction by dephosphorylating specific phosphotyrosine residues on target proteins, thereby facilitating the propagation of growth factor and cytokine signals. ^[12] During embryonic development, SHP2 is essential for the formation of the heart, blood cells, bones, and other tissues. ^[13] Germline mutations in PTPN11 cause developmental disorders such as Noonan syndrome and LEOPARD syndrome, while somatic mutations are frequently implicated in hematologic malignancies and solid tumors by promoting aberrant activation of oncogenic pathways. ^{[14] [15]} In cancer, SHP2 can function as an oncogenic driver by sustaining RAS/RAF/MAPK signaling and supporting tumor cell growth and survival. ^[16] Thus, PTPN11/SHP2 is a critical regulator of both normal cellular processes and disease states, with its dysregulation contributing to developmental syndromes and oncogenesis.

Clinical significance

Missense mutations in the PTPN11 locus are associated with both Noonan syndrome and Leopard syndrome. At least 79 disease-causing mutations in this gene have been discovered. ^[17]

Noonan syndrome

In the case of Noonan syndrome, mutations are broadly distributed throughout the coding region of the gene but all appear to result in hyper-activated, or unregulated mutant forms of the protein. Most of these mutations disrupt the binding interface between the N-SH2 domain and catalytic core necessary for the enzyme to maintain its auto-inhibited conformation. ^[18]

Leopard syndrome

The mutations that cause Leopard syndrome are restricted regions affecting the catalytic core of the enzyme producing catalytically impaired Shp2 variants. ^[19] It is currently unclear how mutations that give rise to mutant variants of Shp2 with biochemically opposite characteristics result in similar human genetic syndromes.

Metachondromatosis

It has also been associated with metachondromatosis. ^[20]

Cancer

Patients with a subset of Noonan syndrome PTPN11 mutations also have a higher prevalence of juvenile myelomonocytic leukemias (JMML). Activating Shp2 mutations have also been detected in neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, lung cancer, colorectal cancer. ^[21] Recently, a relatively high prevalence of PTPN11 mutations (24%) were detected by next-generation sequencing in a cohort of NPM1-mutated acute myeloid leukemia patients, ^[22] although the prognostic significance of such associations has not been clarified. These data suggests that Shp2 may be a proto-oncogene. However, it has been reported that PTPN11/Shp2 can act as either tumor promoter or suppressor. ^[23] In aged mouse model, hepatocyte-specific deletion of PTPN11/Shp2 promotes inflammatory signaling through the STAT3 pathway and hepatic inflammation/necrosis, resulting in regenerative hyperplasia and spontaneous development of tumors. Decreased PTPN11/Shp2 expression was detected in a subfraction of human hepatocellular carcinoma (HCC) specimens. ^[23] The bacterium Helicobacter pylori has been associated with gastric cancer, and this is thought to be mediated in part by the interaction of its virulence factor CagA with SHP2. ^[24]

H Pylori CagA virulence factor

CagA is a protein and virulence factor inserted by Helicobacter pylori into gastric epithelia. Once activated by SRC phosphorylation, CagA binds to SHP2, allosterically activating it. This leads to morphological changes, abnormal mitogenic signals and sustained activity can result in apoptosis of the host cell. Epidemiological studies have shown roles of cagA- positive H. pylori in the development of atrophic gastritis, peptic ulcer disease and gastric carcinoma. ^[25]

Interactions

PTPN11 has been shown to interact with

• CagA, ^[24]
• Cbl gene, ^[26]
• CD117, ^{[27] [28]}
• CD31, ^{[29] [30] [31] [32]}
• CEACAM1, ^[33]
• Epidermal growth factor receptor, ^{[34] [35]}
• Erk ^{[36] [37]}
• FRS2, ^{[38] [39] [40]}
• GAB1, ^{[41] [42]}
• GAB2, ^{[43] [44] [45] [46]}
• GAB3, ^[47]
• Glycoprotein 130, ^{[48] [49] [50]}
• Grb2, ^{[40] [51] [52] [53] [54] [55] [56] [57] [58]}
• Growth hormone receptor, ^{[59] [60]}
• HoxA10, ^[61]
• Insulin receptor, ^{[62] [63]}
• Insulin-like growth factor 1 receptor, ^{[64] [65]}
• IRS1, ^{[66] [67]}
• Janus kinase 1, ^{[48] [51]}
• Janus kinase 2, ^{[51] [68] [69]}
• LAIR1, ^{[70] [71]}
• LRP1, ^[72]
• PDGFRB, ^{[73] [74]}
• PI3K → Akt ^[36]
• PLCG2, ^[43]
• PTK2B, ^[75]
• Ras ^{[36] [37]}
• SLAMF1, ^{[76] [77]}
• SOCS3, ^[48]
• SOS1, ^{[40] [78]}
• STAT3, ^[23]
• STAT5A, ^{[79] [80]} and
• STAT5B. ^[79]

References

1. GRCh38: Ensembl release 89: ENSG00000179295 – Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000043733 – Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Jamieson CR, van der Burgt I, Brady AF, van Reen M, Elsawi MM, Hol F, et al. (December 1994). "Mapping a gene for Noonan syndrome to the long arm of chromosome 12". Nature Genetics. 8 (4): 357–360. doi:10.1038/ng1294-357. PMID   7894486. S2CID   1582162.
6. Freeman RM, Plutzky J, Neel BG (December 1992). "Identification of a human Src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew". Proceedings of the National Academy of Sciences of the United States of America. 89 (23): 11239–11243. Bibcode:1992PNAS...8911239F. doi: 10.1073/pnas.89.23.11239 . PMC   50525 . PMID   1280823.
7. "Entrez Gene: PTPN11 protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1)".
8. Kondo R, Kondo K, Nabeshima K, Nishikimi A, Ishida Y, Shigeoka T, et al. (28 May 2025). "PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution". Frontiers in Immunology. 16: 1573492. doi: 10.3389/fimmu.2025.1573492 . PMC   12151841 . PMID   40503235.
9. Bonetti M, Rodriguez-Martinez V, Paardekooper Overman J, Overvoorde J, van Eekelen M, Jopling C, et al. (15 April 2014). Roehl HH (ed.). "Distinct and overlapping functions of ptpn11 genes in Zebrafish development". PLOS ONE. 9 (4): e94884. Bibcode:2014PLoSO...994884B. doi: 10.1371/journal.pone.0094884 . PMC   3988099 . PMID   24736444.
10. Neel BG, Gu H, Pao L (June 2003). "The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling". Trends in Biochemical Sciences. 28 (6): 284–293. doi:10.1016/S0968-0004(03)00091-4. PMID   12826400.
11. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. (June 2003). "Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia". Nature Genetics. 34 (2): 148–150. doi:10.1038/ng1156. PMID   12717436.
12. Clandinin TR, DeModena JA, Sternberg PW (February 1998). "Inositol trisphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in C. elegans". Cell. 92 (4): 523–533. doi: 10.1016/s0092-8674(00)80945-9 . PMID   9491893.
13. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. (December 2001). "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome". Nature Genetics. 29 (4): 465–468. doi:10.1038/ng772. PMID   11704759.
14. Li SM (2016). "[The Biological Function of SHP2 in Human Disease]". Molekuliarnaia Biologiia (in Russian). 50 (1): 27–33. doi:10.7868/S0026898416010110. PMID   27028808.
15. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. (February 2006). "Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease". American Journal of Human Genetics. 78 (2): 279–290. doi:10.1086/499925. PMC   1380235 . PMID   16358218.
16. Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, et al. (February 2019). "PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas". Molecular Cancer Research. 17 (2): 583–593. doi:10.1158/1541-7786.MCR-18-0777. PMC   6386183 . PMID   30355677.
17. Šimčíková D, Heneberg P (December 2019). "Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases". Scientific Reports. 9 (1) 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC   6901466 . PMID   31819097.
18. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. (January 2007). "Germline gain-of-function mutations in SOS1 cause Noonan syndrome". Nature Genetics. 39 (1): 70–74. doi:10.1038/ng1926. PMID   17143285. S2CID   10222262.
19. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG (March 2006). "PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects". Journal of Biological Chemistry. 281 (10): 6785–6792. doi: 10.1074/jbc.M513068200 . PMID   16377799.
20. Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, et al. (June 2010). "Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene". PLOS Genetics. 6 (6): e1000991. doi: 10.1371/journal.pgen.1000991 . PMC   2887469 . PMID   20577567.
21. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, et al. (December 2004). "Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia". Cancer Research. 64 (24): 8816–8820. doi: 10.1158/0008-5472.CAN-04-1923 . PMID   15604238.
22. Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, et al. (May 2018). "High NPM1 mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML". Blood. 131 (25): 2816–2825. doi:10.1182/blood-2018-01-828467. PMC   6265642 . PMID   29724895.
23. Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, et al. (May 2011). "Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis". Cancer Cell. 19 (5): 629–639. doi:10.1016/j.ccr.2011.03.023. PMC   3098128 . PMID   21575863.
24. Hatakeyama M, Higashi H (December 2005). "Helicobacter pylori CagA: a new paradigm for bacterial carcinogenesis". Cancer Science. 96 (12): 835–843. doi: 10.1111/j.1349-7006.2005.00130.x . PMC   11159386 . PMID   16367902. S2CID   5721063.
25. Hatakeyama M (September 2004). "Oncogenic mechanisms of the Helicobacter pylori CagA protein". Nature Reviews. Cancer. 4 (9): 688–694. doi:10.1038/nrc1433. PMID   15343275. S2CID   1218835.
26. Tanaka Y, Tanaka N, Saeki Y, Tanaka K, Murakami M, Hirano T, et al. (August 2008). "c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130". Molecular and Cellular Biology. 28 (15): 4805–4818. doi:10.1128/MCB.01784-07. PMC   2493370 . PMID   18519587.
27. Tauchi T, Feng GS, Marshall MS, Shen R, Mantel C, Pawson T, et al. (October 1994). "The ubiquitously expressed Syp phosphatase interacts with c-kit and Grb2 in hematopoietic cells". Journal of Biological Chemistry. 269 (40): 25206–25211. doi: 10.1016/S0021-9258(17)31518-1 . PMID   7523381.
28. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA (April 1998). "SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain". Molecular and Cellular Biology. 18 (4): 2089–2099. doi:10.1128/MCB.18.4.2089. PMC   121439 . PMID   9528781.
29. Ilan N, Cheung L, Pinter E, Madri JA (July 2000). "Platelet-endothelial cell adhesion molecule-1 (CD31), a scaffolding molecule for selected catenin family members whose binding is mediated by different tyrosine and serine/threonine phosphorylation". Journal of Biological Chemistry. 275 (28): 21435–21443. doi: 10.1074/jbc.M001857200 . PMID   10801826.
30. Pumphrey NJ, Taylor V, Freeman S, Douglas MR, Bradfield PF, Young SP, et al. (April 1999). "Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31". FEBS Letters. 450 (1–2): 77–83. Bibcode:1999FEBSL.450...77P. doi: 10.1016/S0014-5793(99)00446-9 . PMID   10350061. S2CID   31471121.
31. Hua CT, Gamble JR, Vadas MA, Jackson DE (October 1998). "Recruitment and activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor tyrosine-based inhibitory motif-like binding motifs and substrates". Journal of Biological Chemistry. 273 (43): 28332–28340. doi: 10.1074/jbc.273.43.28332 . PMID   9774457.
32. Jackson DE, Ward CM, Wang R, Newman PJ (March 1997). "The protein-tyrosine phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a distinct signaling complex during platelet aggregation. Evidence for a mechanistic link between PECAM-1- and integrin-mediated cellular signaling". Journal of Biological Chemistry. 272 (11): 6986–6993. doi: 10.1074/jbc.272.11.6986 . PMID   9054388.
33. Huber M, Izzi L, Grondin P, Houde C, Kunath T, Veillette A, et al. (January 1999). "The carboxyl-terminal region of biliary glycoprotein controls its tyrosine phosphorylation and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells". Journal of Biological Chemistry. 274 (1): 335–344. doi: 10.1074/jbc.274.1.335 . PMID   9867848.
34. Schulze WX, Deng L, Mann M (2005). "Phosphotyrosine interactome of the ErbB-receptor kinase family". Molecular Systems Biology. 1 (1): 2005.0008. doi:10.1038/msb4100012. PMC   1681463 . PMID   16729043.
35. Tomic S, Greiser U, Lammers R, Kharitonenkov A, Imyanitov E, Ullrich A, et al. (September 1995). "Association of SH2 domain protein tyrosine phosphatases with the epidermal growth factor receptor in human tumor cells. Phosphatidic acid activates receptor dephosphorylation by PTP1C". Journal of Biological Chemistry. 270 (36): 21277–21284. doi: 10.1074/jbc.270.36.21277 . PMID   7673163.
36. Lai LA, Zhao C, Zhang EE, Feng GS (2004). "14 The Shp-2 tyrosine phosphatase". In Ariño J, Alexander D (eds.). Protein phosphatases. Springer. pp. 275–299. ISBN   978-3-540-20560-9.
37. Neel BG, Gu H, Pao L (June 2003). "The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling". Trends in Biochemical Sciences. 28 (6): 284–293. doi:10.1016/S0968-0004(03)00091-4. ISSN   0968-0004. PMID   12826400.
38. Delahaye L, Rocchi S, Van Obberghen E (February 2000). "Potential involvement of FRS2 in insulin signaling". Endocrinology. 141 (2): 621–628. doi: 10.1210/endo.141.2.7298 . PMID   10650943.
39. Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M (April 2001). "Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction". Oncogene. 20 (16): 1929–1938. doi:10.1038/sj.onc.1204290. PMID   11360177. S2CID   25346661.
40. Hadari YR, Kouhara H, Lax I, Schlessinger J (July 1998). "Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation". Molecular and Cellular Biology. 18 (7): 3966–3973. doi:10.1128/MCB.18.7.3966. PMC   108981 . PMID   9632781.
41. Saito Y, Hojo Y, Tanimoto T, Abe J, Berk BC (June 2002). "Protein kinase C-alpha and protein kinase C-epsilon are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor". Journal of Biological Chemistry. 277 (26): 23216–23222. doi: 10.1074/jbc.M200605200 . PMID   11940581.
42. Rocchi S, Tartare-Deckert S, Murdaca J, Holgado-Madruga M, Wong AJ, Van Obberghen E (July 1998). "Determination of Gab1 (Grb2-associated binder-1) interaction with insulin receptor-signaling molecules". Molecular Endocrinology. 12 (7). Baltimore, Md.: 914–923. doi: 10.1210/mend.12.7.0141 . PMID   9658397.
43. Boudot C, Kadri Z, Petitfrère E, Lambert E, Chrétien S, Mayeux P, et al. (October 2002). "Phosphatidylinositol 3-kinase regulates glycosylphosphatidylinositol hydrolysis through PLC-gamma(2) activation in erythropoietin-stimulated cells". Cellular Signalling. 14 (10): 869–878. doi:10.1016/S0898-6568(02)00036-0. PMID   12135708.
44. Lynch DK, Daly RJ (January 2002). "PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2". The EMBO Journal. 21 (1–2): 72–82. doi:10.1093/emboj/21.1.72. PMC   125816 . PMID   11782427.
45. Zhao C, Yu DH, Shen R, Feng GS (July 1999). "Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1". Journal of Biological Chemistry. 274 (28): 19649–19654. doi: 10.1074/jbc.274.28.19649 . PMID   10391903.
46. Crouin C, Arnaud M, Gesbert F, Camonis J, Bertoglio J (April 2001). "A yeast two-hybrid study of human p97/Gab2 interactions with its SH2 domain-containing binding partners". FEBS Letters. 495 (3): 148–153. Bibcode:2001FEBSL.495..148C. doi:10.1016/S0014-5793(01)02373-0. PMID   11334882. S2CID   24499468.
47. Wolf I, Jenkins BJ, Liu Y, Seiffert M, Custodio JM, Young P, et al. (January 2002). "Gab3, a New DOS/Gab Family Member, Facilitates Macrophage Differentiation". Molecular and Cellular Biology. 22 (1): 231–244. doi: 10.1128/MCB.22.1.231-244.2002 . ISSN   0270-7306. PMC   134230 . PMID   11739737. and associates transiently with the SH2 domain-containing proteins p85 and SHP2
48. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, et al. (January 2003). "SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130". Journal of Biological Chemistry. 278 (1): 661–671. doi: 10.1074/jbc.M210552200 . PMID   12403768.
49. Anhuf D, Weissenbach M, Schmitz J, Sobota R, Hermanns HM, Radtke S, et al. (September 2000). "Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation". Journal of Immunology. 165 (5). Baltimore, Md.: 2535–2543. doi: 10.4049/jimmunol.165.5.2535 . PMID   10946280.
50. Kim H, Baumann H (December 1997). "Transmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cells". Journal of Biological Chemistry. 272 (49): 30741–30747. doi: 10.1074/jbc.272.49.30741 . PMID   9388212.
51. Yin T, Shen R, Feng GS, Yang YC (January 1997). "Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases". Journal of Biological Chemistry. 272 (2): 1032–1037. doi: 10.1074/jbc.272.2.1032 . PMID   8995399.
52. Ganju RK, Brubaker SA, Chernock RD, Avraham S, Groopman JE (June 2000). "Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk". Journal of Biological Chemistry. 275 (23): 17263–17268. doi: 10.1074/jbc.M000689200 . PMID   10747947.
53. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG (July 1994). "Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras". Proceedings of the National Academy of Sciences of the United States of America. 91 (15): 7335–7339. Bibcode:1994PNAS...91.7335B. doi: 10.1073/pnas.91.15.7335 . PMC   44394 . PMID   8041791.
54. Ward AC, Monkhouse JL, Hamilton JA, Csar XF (November 1998). "Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1448 (1): 70–76. doi: 10.1016/S0167-4889(98)00120-7 . hdl: 10536/DRO/DU:30096477 . PMID   9824671.
55. Tang J, Feng GS, Li W (October 1997). "Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor". Oncogene. 15 (15): 1823–1832. doi: 10.1038/sj.onc.1201351 . PMID   9362449.
56. Tang H, Zhao ZJ, Huang XY, Landon EJ, Inagami T (April 1999). "Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells". Journal of Biological Chemistry. 274 (18): 12401–12407. doi: 10.1074/jbc.274.18.12401 . PMID   10212213.
57. Zhang S, Mantel C, Broxmeyer HE (March 1999). "Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells". Journal of Leukocyte Biology. 65 (3): 372–380. doi: 10.1002/jlb.65.3.372 . PMID   10080542. S2CID   38211235.
58. Wong L, Johnson GR (August 1996). "Epidermal growth factor induces coupling of protein-tyrosine phosphatase 1D to GRB2 via the COOH-terminal SH3 domain of GRB2". Journal of Biological Chemistry. 271 (35): 20981–20984. doi: 10.1074/jbc.271.35.20981 . PMID   8702859.
59. Stofega MR, Herrington J, Billestrup N, Carter-Su C (September 2000). "Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B". Molecular Endocrinology. 14 (9). Baltimore, Md.: 1338–1350. doi: 10.1210/mend.14.9.0513 . PMID   10976913.
60. Moutoussamy S, Renaudie F, Lago F, Kelly PA, Finidori J (June 1998). "Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins". Journal of Biological Chemistry. 273 (26): 15906–15912. doi: 10.1074/jbc.273.26.15906 . PMID   9632636.
61. Wang H, Lindsey S, Konieczna I, Bei L, Horvath E, Huang W, et al. (January 2009). "Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia". Journal of Biological Chemistry. 284 (4): 2549–2567. doi: 10.1074/jbc.M804704200 . PMC   2629090 . PMID   19022774.
62. Maegawa H, Ugi S, Adachi M, Hinoda Y, Kikkawa R, Yachi A, et al. (March 1994). "Insulin receptor kinase phosphorylates protein tyrosine phosphatase containing Src homology 2 regions and modulates its PTPase activity in vitro". Biochemical and Biophysical Research Communications. 199 (2): 780–785. Bibcode:1994BBRC..199..780M. doi:10.1006/bbrc.1994.1297. PMID   8135823.
63. Kharitonenkov A, Schnekenburger J, Chen Z, Knyazev P, Ali S, Zwick E, et al. (December 1995). "Adapter function of protein-tyrosine phosphatase 1D in insulin receptor/insulin receptor substrate-1 interaction". Journal of Biological Chemistry. 270 (49): 29189–29193. doi: 10.1074/jbc.270.49.29189 . PMID   7493946.
64. Mañes S, Mira E, Gómez-Mouton C, Zhao ZJ, Lacalle RA, Martínez-A C (April 1999). "Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility". Molecular and Cellular Biology. 19 (4): 3125–3135. doi:10.1128/mcb.19.4.3125. PMC   84106 . PMID   10082579.
65. Seely BL, Reichart DR, Staubs PA, Jhun BH, Hsu D, Maegawa H, et al. (August 1995). "Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein". Journal of Biological Chemistry. 270 (32): 19151–19157. doi: 10.1074/jbc.270.32.19151 . PMID   7642582.
66. Kuhné MR, Pawson T, Lienhard GE, Feng GS (June 1993). "The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp". Journal of Biological Chemistry. 268 (16): 11479–11481. doi: 10.1016/S0021-9258(19)50220-4 . PMID   8505282.
67. Myers MG, Mendez R, Shi P, Pierce JH, Rhoads R, White MF (October 1998). "The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling". Journal of Biological Chemistry. 273 (41): 26908–26914. doi: 10.1074/jbc.273.41.26908 . PMID   9756938.
68. Tauchi T, Damen JE, Toyama K, Feng GS, Broxmeyer HE, Krystal G (June 1996). "Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis". Blood. 87 (11): 4495–4501. doi: 10.1182/blood.V87.11.4495.bloodjournal87114495 . PMID   8639815.
69. Maegawa H, Kashiwagi A, Fujita T, Ugi S, Hasegawa M, Obata T, et al. (November 1996). "SHPTP2 serves adapter protein linking between Janus kinase 2 and insulin receptor substrates". Biochemical and Biophysical Research Communications. 228 (1): 122–127. Bibcode:1996BBRC..228..122M. doi:10.1006/bbrc.1996.1626. PMID   8912646.
70. Fournier N, Chalus L, Durand I, Garcia E, Pin JJ, Churakova T, et al. (August 2000). "FDF03, a novel inhibitory receptor of the immunoglobulin superfamily, is expressed by human dendritic and myeloid cells". Journal of Immunology. 165 (3). Baltimore, Md.: 1197–1209. doi: 10.4049/jimmunol.165.3.1197 . PMID   10903717.
71. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, et al. (August 1997). "LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes". Immunity. 7 (2): 283–290. doi: 10.1016/S1074-7613(00)80530-0 . hdl: 2066/26173 . PMID   9285412.
72. Betts GN, van der Geer P, Komives EA (June 2008). "Structural and functional consequences of tyrosine phosphorylation in the LRP1 cytoplasmic domain". Journal of Biological Chemistry. 283 (23): 15656–15664. doi: 10.1074/jbc.M709514200 . PMC   2414285 . PMID   18381291.
73. Keilhack H, Müller M, Böhmer SA, Frank C, Weidner KM, Birchmeier W, et al. (January 2001). "Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1". The Journal of Cell Biology. 152 (2): 325–334. doi:10.1083/jcb.152.2.325. PMC   2199605 . PMID   11266449.
74. Lechleider RJ, Sugimoto S, Bennett AM, Kashishian AS, Cooper JA, Shoelson SE, et al. (October 1993). "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor". Journal of Biological Chemistry. 268 (29): 21478–21481. doi: 10.1016/S0021-9258(20)80562-6 . PMID   7691811.
75. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, et al. (September 2000). "SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells". Journal of Biological Chemistry. 275 (36): 27845–27850. doi: 10.1074/jbc.M003428200 . PMID   10880513.
76. Howie D, Simarro M, Sayos J, Guirado M, Sancho J, Terhorst C (February 2000). "Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation". Blood. 99 (3): 957–965. doi: 10.1182/blood.V99.3.957 . PMID   11806999.
77. Morra M, Lu J, Poy F, Martin M, Sayos J, Calpe S, et al. (November 2001). "Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells". The EMBO Journal. 20 (21): 5840–5852. doi:10.1093/emboj/20.21.5840. PMC   125701 . PMID   11689425.
78. Chin H, Saito T, Arai A, Yamamoto K, Kamiyama R, Miyasaka N, et al. (October 1997). "Erythropoietin and IL-3 induce tyrosine phosphorylation of CrkL and its association with Shc, SHP-2, and Cbl in hematopoietic cells". Biochemical and Biophysical Research Communications. 239 (2): 412–417. Bibcode:1997BBRC..239..412C. doi:10.1006/bbrc.1997.7480. PMID   9344843.
79. Yu CL, Jin YJ, Burakoff SJ (January 2000). "Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation". Journal of Biological Chemistry. 275 (1): 599–604. doi: 10.1074/jbc.275.1.599 . PMID   10617656.
80. Chughtai N, Schimchowitsch S, Lebrun JJ, Ali S (August 2002). "Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells". Journal of Biological Chemistry. 277 (34): 31107–31114. doi: 10.1074/jbc.M200156200 . PMID   12060651.

Further reading

• Marron MB, Hughes DP, McCarthy MJ, Beaumont ER, Brindle NP (2000). "Tie-1 Receptor Tyrosine Kinase Endodomain Interaction with SHP2: Potential Signalling Mechanisms and Roles in Angiogenesis". Angiogenesis. Advances in Experimental Medicine and Biology. Vol. 476. pp. 35–46. doi:10.1007/978-1-4615-4221-6_3. ISBN   978-1-4613-6895-3. PMID   10949653.
• Carter-Su C, Rui L, Stofega MR (2000). "SH2-B and SIRP: JAK2 binding proteins that modulate the actions of growth hormone". Recent Progress in Hormone Research. 55: 293–311. PMID   11036942.
• Ion A, Tartaglia M, Song X, Kalidas K, van der Burgt I, Shaw AC, et al. (October 2002). "Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome". Human Genetics. 111 (4–5): 421–427. doi:10.1007/s00439-002-0803-6. PMID   12384786. S2CID   27085702.
• Hugues L, Cavé H, Philippe N, Pereira S, Fenaux P, Preudhomme C (June 2005). "Mutations of PTPN11 are rare in adult myeloid malignancies". Haematologica. 90 (6): 853–854. PMID   15951301.
• Tartaglia M, Gelb BD (2005). "Germ-line and somatic PTPN11 mutations in human disease". European Journal of Medical Genetics. 48 (2): 81–96. doi:10.1016/j.ejmg.2005.03.001. PMID   16053901.
• Ogata T, Yoshida R (June 2005). "PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes". Pediatric Endocrinology Reviews. 2 (4): 669–674. PMID   16208280.
• Feng GS (January 2007). "Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation". Cell Research. 17 (1): 37–41. doi: 10.1038/sj.cr.7310140 . PMID   17211446.
• Edouard T, Montagner A, Dance M, Conte F, Yart A, Parfait B, et al. (July 2007). "How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms?". Cellular and Molecular Life Sciences. 64 (13): 1585–1590. doi:10.1007/s00018-007-6509-0. PMC   11136329 . PMID   17453145. S2CID   25934330.

External links

• GeneReviews/NCBI/NIH/UW entry on Noonan syndrome